Chang-Kun Choi, DO
Internal Medicine · Tucson, AZNPI 1760577241
Payments from drug & device makers
Across 289 payments — averaging $45.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- AstraZeneca$889
- GSK$803
- Johnson & Johnson$591
- Boehringer Ingelheim$319
- Regeneron Healthcare Solutions, Inc.$303
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$3002%
- Travel & lodging$3,60227%
- Food & beverage$6,37948%
- Education$3,00023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 34 | $7,595 |
| AstraZeneca | 27 | $889 |
| GSK | 54 | $803 |
| Johnson & Johnson(3 entities) | 9 | $591 |
| Boehringer Ingelheim | 15 | $319 |
| Regeneron Healthcare Solutions, Inc. | 13 | $303 |
| Amgen | 13 | $257 |
| Actelion Pharmaceuticals US, Inc. | 11 | $242 |
| Electromed, Inc. | 28 | $240 |
| Grifols USA, LLC | 12 | $235 |
| Merck | 12 | $223 |
| Jazz Pharmaceuticals Inc. | 9 | $201 |
| ZOLL Respicardia, Inc. | 1 | $138 |
| Boston Scientific | 3 | $135 |
| Medtronic | 1 | $102 |
| Daiichi Sankyo Inc. | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Mylan Specialty L.p. | 4 | $79 |
| Genentech USA, Inc. | 4 | $78 |
| Insmed, Inc. | 3 | $76 |
| Philips North America LLC | 3 | $56 |
| Pulmonx Corporation | 2 | $49 |
| Harmony Biosciences LLC | 2 | $46 |
| Viatris Specialty LLC | 2 | $43 |
| Blueprint Medicines Corporation | 2 | $39 |
| Verona Pharma, Inc. | 1 | $34 |
| Vapotherm Inc | 1 | $33 |
| Covis Pharma GmbH | 1 | $31 |
| Baxter Healthcare | 2 | $31 |
| Caris MPI, Inc. | 1 | $29 |
| Novartis | 2 | $29 |
| Lilly USA, LLC | 2 | $26 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Sanofi | 1 | $19 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Sobi, Inc | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,555
- ION$3,000
- MONARCH$377
- IMFINZI$300
- remede System$138
- TAGRISSO$125
- NUCALA$103
- Signia$102
How this compares
$13,281 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 312 | $243,813 |
| Breo ElliptaFluticasone/Vilanterol | 181 | $85,020 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 42 | $29,628 |
| Spiriva RespimatTiotropium Bromide | 28 | $24,115 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $21,571 |
| Spiriva HandihalerTiotropium Bromide | 25 | $12,768 |
| Advair HfaFluticasone Propion/Salmeterol | 39 | $12,636 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $12,120 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $11,942 |
| Arnuity ElliptaFluticasone Furoate | 33 | $10,985 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,311 |
| Wixela InhubFluticasone Propion/Salmeterol | 41 | $8,956 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 306 | $7,897 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $5,836 |
| Varenicline Tartrate | 16 | $4,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta, Anoro Ellipta | $803 | $362,249580 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $319 | $53,74370 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $889 | $33,51387 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Tucson
- Robert MutterperlTucson$5.3M
- Nebojsa SkrepnikTucson$4.7M
- Franz RischardTucson$3.7M
- Girish KaramchandaniTucson$2.9M
- Siddharth SinghalTucson$1.3M
- Rajesh JanardhananTucson$983K
- Carl DienerTucson$750K
- Roxana RodriguezTucson$547K
- Mona SelejTucson$440K
- Muhammad HusnainTucson$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.